Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant for improving walking ability in incomplete spinal cord injury
2022-001522-30Phase 2Active
- Sponsor
- Fundación Hospital Nacional de Parapléjicos
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rimonabant in spinal cord injury (SCI), sponsored by Fundación Hospital Nacional de Parapléjicos. Primary endpoint: Six-minute walking distance. Started Oct 2022; status: active.
02
Drugs
rimonabant
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on 2022-001522-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001522-30.